Swiss-based research informatics provider Genedata today announced its collaboration with Tokyo Medical University, AMR Inc., and Leica Microsystems in a proteomics research initiative aiming at the identification of metastatic biomarkers for the discovery and validation of new protein drug targets.
In the project, proteins extracted from lung and endocrine carcinoma FFPE tissue collections are analyzed using state-of-the-art MS-based proteomic methodologies. Formalin-fixed and paraffin-embedded (FFPE) tissue samples have been extensively collected and annotated in hospitals around the globe representing an invaluable resource to study the progression of diseases in detail.
For the downstream molecular analysis, Genedata provides Expressionist, its modular enterprise system for biomarker discovery, along with comprehensive professional services. The high-throughput capabilities for quality assessment, pre-processing and integrated analysis make Genedata Expressionist a superior choice to handle the breadth and complexity of the mass-spectrometry based proteomics data, leading to the detection of molecular effects and interactions that would have otherwise gone unnoticed.
Professor Toshihide Nishimura, Department of Surgery, Tokyo Medical University, and Senior Advisor, Expression Pathology Inc. (USA), said: “Genedata`s support for our proteomics ‘star alliance’ is proving to be of outstanding value. Genedata Expressionist, as a capable high-throughput solution for proteomics analysis, is the key to unlocking a treasure chest of clinical samples for metastatic biomarker research that were intractable before.”
“We are very pleased with our unique contribution,” said Dr. Frank Staubli, Representative Director of Genedata KK. “MS-based retrospective proteomics represents an opportunity as well as a challenge for an integrated data processing and analysis system. Genedata Expressionist`s performance exceeds our expectations, and shows great potential for the scope of the collaboration.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.